<DOC>
	<DOCNO>NCT01342640</DOCNO>
	<brief_summary>This single arm , open label , multicenter study evaluate safety change hemoglobin level Mircera ( C.E.R.A . ; methoxy polyethylene glycol-epoetin beta ) patient chronic renal anemia dialysis . Patients receive recommend start dose 1.2 microgram Mircera subcutaneously every 4 week . The start dose dependent patient 's weight . Dose adjustment may require due inadequate excessive treatment response . The anticipated time study treatment 28 week .</brief_summary>
	<brief_title>A Study Mircera ( C.E.R.A . ) Patients With Pre-Dialysis Chronic Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<criteria>Adult patient , age &gt; /=18 year Diagnosis chronic renal anemia Not dialysis Hemoglobin concentration &lt; 10 g/dl No erythropoiesis stimulate agent ( ESA ) therapy 3 month study start Estimated glomerular filtration rate ( EGFR ) &lt; 60 ml/min &gt; /=20 ml/min Adequate iron status Transfusion red blood cell previous 2 month Poorly control hypertension Significant acute chronic bleeding , e.g . gastrointestinal bleed Active malignant disease ( except nonmelanoma skin cancer ) Hemolysis Hemoglobinopathies , e.g . sicklecell disease , thalassemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>